Inactivated whole virus influenza A (H5N1) vaccine [18]

Emerging Infectious Diseases

Volumn 13, Issue 5, 2007, Pages 807-808

  Vajo, Zoltan ^a,d   Kosa, Lajos ^a   Visontay, Ildiko ^b   Jankovics, Mate ^c   Jankovics, Istvan ^b  

^a National Center for Allergy and Immunology   (Hungary)

^b NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d NONE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

AVIAN INFLUENZA; CLINICAL TRIAL; CULTURE MEDIUM; DOSE RESPONSE; ECCHYMOSIS; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LETTER; MALAISE; PROPHYLAXIS; SHIVERING; VIRUS STRAIN;

EID: 34247897126     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1305.061248     Document Type: Letter

References (10)

1. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352:333-40.
2. Dennis C. Flu-vaccine makers toil to boost supply. Nature. 2006;440:1099.
3. Takatsy G. Purified precipitated virus obtained by a new simple method. Acta Med Acad Sci Hung. 1952;3:185-91.
4. License number: OGYI-T-8998/01. Budapest: National Institute of Pharmacology; 1995.
5. European Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96). Brussels: European Agency for the Evaluation of Medicinal Products; March 12, 1997.
6. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). Brussels: European Agency for the Evaluation of Medicinal Products; April 5, 2004.
7. Klimov A, Cox N. Serologic diagnosis of influenza virus infections by hemagglutination inhibition. Influenza laboratory course. Atlanta: Centers for Disease Control and Prevention; 2003.
8. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immungenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354:1343-51.
9. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al. Safety and immunogenicity of an inactivated splitvirion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006;367:1657-64.
10. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006;368:991-7.